Dear Editor,

In the journal, a comprehensive review of COVID-19 was published to summarize the nature of SARS-CoV-2 and the timing of its clinical characteristics.[@bib0001] Since the emerging infectious disease emerged in Wuhan, China, it has spread rapidly around the world.[@bib0002] According to the latest epidemiological statistics, by March 20, 2020, the number of confirmed cases worldwide has exceeded 240,000, with a fatality rate of 4.1%. The course of COVID-19 illness can progress rapidly, causing acute respiratory distress syndrome, septic shock, metabolic acidosis and blood coagulation dysfunction.[@bib0001] ^,^ [@bib0003] ^--^ [@bib0005] Due to a previous lack of in-depth research on the characteristics of the disease, the mortality of severe illness is high.[@bib0004] It is very important to analyse the clinical characteristics of COVID-19 in international regions and identify risk factors to reduce the incidence of severe and critical illness in the early stage. In this letter, we present discrepancies of patients with different disease severities and risk factors for severe COVID-19 by comparing and analysing epidemiological and clinical data of 167 confirmed patients in Anhui, China.

In the present study, the rate of severely ill patients was as high as 17.9%. Comparisons of demographics and clinical characteristics between 30 severe and 137 non-severe patients are shown in [Table 1](#tbl0001){ref-type="table"} . The mean age was 49.03 years in severe patients and 40.83 years in non-severe patients, with a significant difference (*p* = 0.007. There were 95 males (56.89%) and 72 females (43.11%); however, there was no significant differences in sex between the two groups. Among 167 patients, 146 had fever (87.43%), 132 had cough (79.04%) and 61 had shortness of breath (36.53%). The prevalence of shortness of breath was 73.33% in severe patients, which was significantly greater than the 28.47% prevalence in non-severe patients (*p* \< 0.001). There were 44 patients (26.35%) with comorbidities, of which 9 had multiple comorbidities (5.39%). Among patients with diabetes, severe cases were significantly more common than in non-severe patients (*p* \< 0.001). Compared to non-severe patients, fingertip oxygen saturation decreased significantly in severe patients (*p* \< 0.001), which predisposed patients with chronic obstructive pulmonary disease to acute exacerbation. Since SARS-CoV-2 affected multiple organs by binding angiotensin converting enzyme 2 (ACE2) receptor[@bib0006] and many severe COVID-19 patients had comorbidities, multidisciplinary team (MDT) consultation played an important role in reducing the mortality of severe infection. There were significant differences in the use of mechanical ventilation, glucocorticoids and immunoglobulin between severe and non-severe patients (all *p* \< 0.05).Table 1Comparison of demographics and clinical characteristics between severe and non-severe patients with COVID-19.Table 1VariablesAll patients\
(*n* = 167)Disease severityNon-severe\
(*n* = 137)Severe\
(*n* = 30)P-value**Age, years**42.31(15.29)40.83(15.47)49.03(12.60)0.007**Mal sex, n (%)**95(56.89%)75(54.74%)20(66.67%)0.232**BMI, kg/m^2^**24.52(3.41)24.22(22.19,26.12)24.55(3.19)0.830**Exposure history, n (%)**History of cluster onset91(54.49%)NANANAExposure to Wuhan78(46.71%)60(43.80%)18(60.00%)0.107Non-exposure to Wuhan12(7.19%)12(8.76%)0(0.00%)0.196**Signs and symptoms at admission, n (%)**Fingertip oxygen saturation (%)98.00(96.00,99.00)98.00(97.00,99.00)94.00(91.00,97.25)0.000Cough132(79.04%)106(77.37%)26(86.67%)0.257Fever146(87.43%)118(86.13%)28(93.33%)0.439Shortness of breath61(36.53%)39(28.47%)22(73.33%)0.000Sore throat25(14.97%)21(15.33%)4(13.33%)1.000Diarrhea56(33.53%)50(36.50%)6(20.00%)0.083Nausea and vomiting17(10.18%)16(11.68%)1(3.33%)0.300Multiple symptoms147(88.02%)119(86.86%)28(93.33%)0.497**Comorbidity, n (%)**Any44(26.35%)30(21.90%)14(46.67%)0.005Cardiovascular diseases24(14.37%)17(12.41%)7(23.33%)0.209Diabetes11(6.59%)4(2.92%)7(23.33%)0.000Digestive diseases9(5.39%)6(4.38%)3(10.00%)0.430Respiratory diseases4(2.40%)2(1.46%)2 (6.67%)0.148Central nervous system diseases2(1.20%)2(1.46%)0(0.00%)1.000Hematological diseases1(0.60%)0(0.00%)1(3.33%)0.180Immune diseases2(1.20%)2(1.46%)0(0.00%)1.000**Treatment, n (%)**Oxygen therapy133(79.64%)104(75.91%)29(96.67%)0.011Mechanical ventilation22(13.17%)2(1.46%)20(66.67%)0.000  Invasive4(2.40%)0(0.00%)4(13.33%)0.001  Non-invasive18(10.78%)2(1.46%)16(53.33%)0.000Antiviral treatment166(99.40%)137(100.00%)29(96.67%)0.180Glucocorticoids42(25.15%)20(14.60%)22(73.33%)0.000Immunoglobulin27(16.17%)9(6.57%)18(60.00%)0.000**Length of stay in hospital**15.00(12.00,20.00)15.00(12.00,20.00)17.06(4.98)0.260[^2][^3][^4]

[Table 2](#tbl0002){ref-type="table"} presents comparisons of laboratory parameters between severe and non-severe patients. Lymphocyte, CD4 and CD8 cell counts were decreased significantly in severe patients compared to non-severe patients (*p* = 0.004, 0.021 and 0.002), suggesting that T lymphocytes were seriously destroyed. The increased level of c-reactive protein (CRP) in severe patients was significantly higher than that in non-severe patients (*p* = 0.001). Interleukin-6 (IL-6) levels increased in 122 patients (73.05%); the increase was more significant in severe patients than in non-severe (*p* = 0.001). By clearing or blocking inflammatory factors,[@bib0007] artificial liver therapy and tocilizumab, a monoclonal antibody of IL-6 receptor, may prevent serious injuries in the lungs in severe patients. The lactate dehydrogenase (LDH) concentration was higher and the albumin concentration was lower in severe patients, with significant differences (*p* = 0.002 and *p*\<0.001). In severe patients, the fibrinogen concentration was significantly higher (*p* = 0.008) than in non-severe patients, suggesting that severe patients were more likely to experience myocardial infarction or sudden death. Between the two groups, there was a significant difference in the neutrophil to lymphocyte ratio (NLR), a predictor for severe infection[@bib0008] (*p* = 0.033). Other laboratory parameters that changed in COVID-19 patients were not significantly different between the two groups (all *p* \> 0.05).Table 2Comparison of laboratory parameters between severe and non-severe patients with COVID-19.Table 2VariablesAll patients\
(*n* = 167)Disease severityNon-severe\
(*n* = 137)**Severe**\
**(*n*** **=** **30)P-valueBlood routine**Leucocytes (× 10⁹ /L)4.99(3.85,6.25)5.00(3.88,6.24)4.62(3.49,6.83)0.552 normal132(79.04%)Neutrophils (× 10⁹/L)3.39(2.32,4.46)3.43(2.39,4.40)3.93(2.23)0.812 Increased14(8.38%)10(7.30%)4(13.33%)0.474Lymphocytes (× 10⁹/L)1.13(0.77,1.41)1.17(0.86,1.42)0.77(0.65,1.32)0.006 Decreased77(46.11%)56(40.88%)21(70.00%)0.004**Blood biochemistry**Albumin(/µL)41.20(38.90,43.90)41.60(39.75,44.35)38.89(3.74)0.000 Decreased57(34.13%)38(27.74%)19(63.33%)0.000ALT (U/L)23.00 (15.00,37.00)23.00(13.50,37.00)24.00(16.75,37.00)0.551AST (U/L)26.00(20.00,33.00)25.00(19.00,33.00)28.00(23.00,30.25)0.108LDH (U/L)233.00(201.00,281.00)232.00(197.50,266.50)291.20(84.83)0.002 Increased66(39.52%)48(35.04%)18(60.00%)0.011Glucose (mmol/l)5.95(5.42,6.78)5.90(5.37,6.73)6.23(5.54,7.71)0.141Creatine kinase (U/L)65.00(44.00,88.00)65.00(45.50,88.00)65.00(43.75,91.00)0.796CK-MB (U/L)8.00(5.00,12.00)8.00(4.99,12.00)9.50(5.75,13.00)0.329Blood urea nitrogen (mmol/L)3.80(3.00,4.70)3.70(3.05,4.70)4.10(2.98,5.30)0.191Creatinine clearance(ml/min)64.91(16.52)64.01(16.43)74.50(53.50,80.00)0.135 Decreased134(80.24%)112(81.75%)22(73.33%)0.294**Coagulation function**D-dimer (mg/L)0.28(0.20,0.53)0.26(0.19,0.51)0.35(0.23,0.58)0.106Fibrinogen (g/L)3.29(2.56,4.13)3.17(2.55,3.84)4.04(1.46)0.008 Increased47(28.14%)31(22.63%)16(53.33%)0.001**Other related biomarkers**Procalcitonin (ng/mL)0.03(0.02,0.06)0.03(0.02,0.05)0.05(0.02,0.10)0.101 Increased47(28.14%)33(24.09%)14(46.67%)0.013CRP (mg/L)12.40(2.70,30.60)9.00(2.35,24.45)30.35(8.75,74.05)0.001 Increased107(64.07%)83(60.58%)24(80.00%)0.045IL-6(pg/ml)17.50(5.30,36.10)15.40(5.05,28.90)36.20(16.25,59.90)0.001 Increased122(73.05%)96(70.07%)26(86.67%)0.064NLR3.12(1.93,4.83)3.05(1.86,4.43)4.77(3.44)0.033CD4 cell count(/µL)465.63(263.82)490.40(232.64)282.00(183.00,574.75)0.002 Decreased74(44.31%)55(40.15%)19(63.33%)0.021CD8 cell count(/µL)291.00(190.00,425.00)316.00(234.50,452.25)191.00(135.75,326.50)0.002 Decreased41(24.55%)27(19.71%)14(46.67%)0.002CD4/CD81.51(1.08,1.91)1.51(1.11,1.91)1.51(0.71)0.904[^5][^6][^7]

[Fig. 1](#fig0001){ref-type="fig"} A shows the risk factors for severe patients based on the results of mono-factor logistic regression analysis. The analysis demonstrated that increased age, existence of comorbidities, NLR, increased levels of CRP, LDH and IL-6, decreased fingertip oxygen saturation, decreased lymphocytes, and CD4 and CD8 cell counts were risk factors for severe infections (all *p*\<0.05). The results of multi-factor logistic regression analysis then proved that fingertip oxygen saturation (OR=0.545, 95%CI: 0.391--0.759, *p*\<0.001) and decreased CD4 cell count (OR=0.996, 95%CI: 0.992--1.000, *p* = 0.039) were independent risk factors, as shown in [Fig. 1](#fig0001){ref-type="fig"}B.Fig. 1Forest plots of hazard ratios (HRs) for severe COVID-19 illness.A. Mono-factor logistic regression analysis was used to analyse risk factors for severe illness using R software; B. Multi-factor logistic regression analysis was used to analyse independent risk factors for severe illness using R software.**Notes**: *P*\<0.05 indicates a risk factor in [Fig. 1](#fig0001){ref-type="fig"}A and an independent risk factor in [Fig. 1](#fig0001){ref-type="fig"}B for severe patients.Fig. 1

There are still no specific therapies for COVID-19[@bib0001]; nevertheless, assessing risk factors and symptomatic treatment in the early stage of the disease can improve the prognosis. Of 167 patients, 99.40% received initial antiviral therapy using lopinavir and ritonavir (400 mg/100 mg, bid) for no more than 10 days and/or atomized inhalation of interferon-α except for a 2-year-old patient, who was given interferon-α only, and 25.15% of patients received 40 mg methylprednisolone for 3 to 5 days. A total of 16.17% of patients were supported with immunoglobulins, and 13.18% of patients were managed with suitable oxygen therapy. All severe patients received MDT consultation, and three critical patients were treated with artificial liver therapy every other day, three times consecutively. Finally, all patients in our study, both severe or non-severe, improved and were discharged without death.

The clinical characteristics of 167 COVID-19 patients are summarized in [Tables 1](#tbl0001){ref-type="table"} and [2](#tbl0002){ref-type="table"}. The similarities and differences between severe and non-severe patients in this letter suggested that elderly patients with multiple comorbidities, hypoxia, decreased CD4 and CD8 cell counts and increased levels of CRP and IL-6 are all closely associated with disease severity and prognosis, which should be assessed seriously during diagnosis and treatment. A rapid decline in T lymphocytes and significant increases in the levels of inflammatory factors, including CRP and IL-6, can be clinical warnings of severe infection. MDT consultation and artificial liver therapy are very effective methods for severe patients with COVID-19. With these integrated prevention and treatment strategies, there will be a good prognosis for COVID-19.
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